Bioasis (BTI.V) is a company that is delivering hope to patients suffering with neurological diseases and disorders. It is the Blood-Brain Barrier delivery company. The Blood-Brain Barrier…
BTI.V
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain….
Bioasis is a preclinical biopharmaceutical company focused on research and early-stage development of technologies and products for the treatment of patients with the central nervous system, or CNS, diseases,…
Dr. Mario Saltarelli, Director of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an…
Bioasis Technologies (BTI.V) hired Shadow Lake Group, and affiliate, SLG Europe BV, as a business development adviser earlier this week, according to a press release. This one’s a…
Bioasis Technologies (BTI.V) announces today that the Japanese Patent Office (JPO) has issued Japanese Patent No.2019-189551 Notice of Allowance for the Company’s xB3™-IDS fusion proteins. “We are excited about…
Bioasis (TSXV:BTI; OTCQB:BIOAF), a biopharmaceutical company, has the potential to transform the treatment of brain disorders by bringing new, innovative technologies to the forefront. Their scientific research has led…
Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company’s ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective…
Bioasis Technologies (BTI.V) announced positive results today from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis (MS). “These…